Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug

 ADHD in the News 2025-03-06


Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has issued another. This time, the product pull covers about 1.48 million bottles of the generic attention deficit hyperactivity disorder (ADHD) drug atomoxetine.

View Article: Fierce Pharma, March 4, 2025




Other Articles in this Edition

Why ADHD Drugs Are So Hard to Find

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug

ADHD diagnoses on the rise among working-age adults in the United States

Changing the Perception of ADHD in the Black Community (Opinion)

Strong link between Western diet during pregnancy and ADHD

Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents

One in five people who use alcohol and other drugs have symptoms of ADHD

WVU research reveals adults with disabilities misuse prescription drugs at high rates

Does getting ADHD drugs via telehealth increase addiction risk?

Study Offers Practical Recommendations to Improve Diagnosis and Care for Women With ADHD

Genes and childhood trauma both play a role in adult ADHD symptoms, study finds

Stimulant medication improves working memory of children with ADHD, study finds

Ramadan Reset: A Mental Health Guide for All

Neuroscientist Warns Of The Common Habit That Destroys The Success And Thinking Ability Of Even The Most Brilliant People